Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357107 | 1.00 | LDHA (0.38) | LDHASRRFFAR3CYP2C9HDAC3 | |
| SCHEMBL30532234 | 0.88 | TSHR (0.33) | TSHR | |
| SCHEMBL10777977 | 0.81 | HDAC1 (0.41) | LDHASRRFFAR3HDAC3HDAC1 | |
| SCHEMBL29411100 | 0.78 | GAA (0.41) | LMNAEGLN1 | |
| SCHEMBL10780876 | 0.78 | CA2 (0.42) | ACE2TSHR | |
| SCHEMBL29199347 | 0.77 | LDHA (0.40) | LDHASRRCYP2C9TSHRLMNA | |
| SCHEMBL10031543 | 0.76 | — | — | |
| SCHEMBL16445585 | 0.74 | GPR84 (0.48) | ACE2TSHR | |
| SCHEMBL2021291 | 0.74 | USP2 (0.44) | LDHASRRFFAR3HDAC3HDAC1 | |
| SCHEMBL3838841 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569275-A1 | A PROCESS FOR THE HYDROGENATION OF KETOESTERS | Lonza Ltd. (CH) | 2013-03-20 | — | — | EP | claimed |
| US-20120016153-A1 | PROCESS FOR THE HYDROGENATION OF KETOESTERS | LONZA LTD (CH) | 2012-01-19 | — | — | US | claimed |
| WO-2011141160-A1 | A PROCESS FOR THE HYDROGENATION OF KETOESTERS | LONZA LTD (CH) | 2011-11-17 | — | — | WO | claimed |
| EP-2386536-A1 | A process for the hydrogenation of ketoesters | Lonza Ltd. (CH) | 2011-11-16 | — | — | EP | claimed |
| US-8037666-B2 | Mower with an lightening device including torsion bars | KUHN S.A. (FR) | 2011-10-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016153-A1 | PROCESS FOR THE HYDROGENATION OF KETOESTERS | CBR3, BCKDK, PAOX | LDHA 222/4885SRR 557/4885FFAR3 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.